Clinical Trials Browser

INDUSTRY × Melanoma × Immune Checkpoint Inhibitors × Clear all

NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04625205 2025-04-06

A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma

Phase 1 Terminated

22 enrolled

Dermatologic

Melanoma

NCT03504488 2025-01-15

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Phase 1/2 Completed

132 enrolled

BreastDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Triple Negative Breast Neoplasms

NCT05037825 2022-04-27

PARADIGM

Recruiting

800 enrolled

BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Triple Negative Breast Neoplasms

NCT02574533 2017-09-27

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

Phase 1 Completed

2 enrolled

Dermatologic

Melanoma